Product image of Linagliptin Sandoz (Linagliptin) supplied by GNH India

Linagliptin Sandoz

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptin Sandoz (Linagliptin)

Linagliptin, the active ingredient in Linagliptin Sandoz, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used with diet and exercise.

GNH India supplies Linagliptin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. It ensures timely delivery and reliable supply chain management for its partners.

Manufacturer / TM Owner

Sandoz A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

  • Type 2 diabetes mellitus (monotherapy): reduces HbA1c levels and improves fasting glucose as an add‑on to diet and exercise.
  • Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when combined with metformin, sulfonylureas or insulin.
  • Type 2 diabetes with renal impairment: provides glucose control without the need for dose adjustment in patients with reduced kidney function.

How It Works

  • Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), preventing the breakdown of the incretin hormones GLP‑1 and GIP. Elevated incretin levels increase glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, thereby lowering post‑prandial and fasting blood glucose concentrations.

Side Effects

Linagliptin may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

  • Upper respiratory tract infection
  • Nasopharyngitis
  • Headache
  • Dizziness
  • Gastrointestinal discomfort (nausea, abdominal pain)
  • Skin rash

Serious or Rare Side Effects

  • Pancreatitis
  • Severe hypersensitivity reactions (angioedema, anaphylaxis)
  • Hepatic enzyme elevations
  • Bullous pemphigoid
  • Hypoglycaemia when combined with insulin or sulfonylureas

Precautions & Warnings

When prescribing linagliptin, clinicians should consider several safety aspects.

  • Renal impairment: no dose adjustment required but monitor renal function regularly.
  • Hepatic impairment: use with caution in patients with moderate hepatic disease.
  • Concomitant sulfonylureas or insulin: increased risk of hypoglycaemia; adjust co‑medication as needed.
  • Pregnancy and lactation: safety not established; avoid unless benefits outweigh potential risks.
  • Cardiovascular disease: no specific contraindication, but monitor patients with unstable cardiac conditions.
  • Store at ambient temperature (below 25 °C): keep in the original packaging, protect from moisture and light.

Avoid Interactions

Linagliptin can interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampicin) may markedly reduce linagliptin exposure.
  • Co‑administration with insulin secretagogues may precipitate severe hypoglycaemia.
  • Use with other DPP‑4 inhibitors is not recommended due to overlapping mechanisms.

Moderate Interactions (Monitor Closely)

  • Diuretics may increase the risk of dehydration.
  • ACE inhibitors may enhance hypotensive effects.
  • Anticoagulants (e.g., warfarin) may require INR monitoring.
  • Antacids containing aluminium/magnesium may slightly affect absorption.
  • NSAIDs may increase the risk of renal impairment in susceptible patients.

Frequently Asked Questions

Linagliptin Sandoz is used to improve glycaemic control in adult patients with type 2 diabetes mellitus. It is prescribed as part of a comprehensive treatment plan that includes diet, exercise and, when appropriate, other antidiabetic agents.

Linagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition raises levels of the incretin hormones GLP‑1 and GIP, which stimulate insulin release and suppress glucagon secretion in a glucose‑dependent manner, thereby lowering blood glucose.

The prescribed dose of linagliptin is determined by the treating physician based on the individual patient's clinical profile, renal and hepatic function, and concomitant therapies. The prescriber will select the appropriate strength and dosing schedule.

Safety of linagliptin during pregnancy and lactation has not been established. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and only under close medical supervision.

To order Linagliptin Sandoz, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Linagliptin shares the same class mechanism as other DPP‑4 inhibitors but is distinguished by its high binding affinity and primarily non‑renal elimination, allowing use without dose adjustment in patients with renal impairment, unlike some alternatives that require renal dosing modifications.

Store Linagliptin Sandoz tablets at ambient temperature, preferably below 25 °C. Keep the product in its original blister pack or container, protect it from moisture, heat and direct sunlight, and ensure the packaging remains tightly closed until use.

Linagliptin Sandoz is taken orally, usually once daily, with or without food. Patients should follow the prescribing physician’s instructions regarding timing and whether it should be taken at a specific time of day.

Serious risks include pancreatitis, severe hypersensitivity reactions such as angioedema or anaphylaxis, and rare dermatologic conditions like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, signs of allergic reaction, or unusual skin eruptions.

Linagliptin Sandoz should be avoided in patients with a known hypersensitivity to linagliptin or any component of the formulation. Caution is also advised for individuals with a history of pancreatitis or severe hepatic impairment, and it is not recommended for use in pregnancy or lactation unless clearly justified.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT